RxDoctor Payments Data

Zaineb Daud, MD

Neurology · Philadelphia, MSNPI 1568468908

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 446 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations.

$8,191in general payments, 2019–2025

Across 446 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$1K
  • Lilly USA, LLC$938
  • Teva Pharmaceuticals USA, Inc.$732
  • Pfizer$570
  • SK Life Science, Inc.$540
  • Novartis$412
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$8,180100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,191 in reported general payments places this provider in the 65th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$102,219
Medicare patients
393
Services billed
1,680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate82$466,300
Aimovig AutoinjectorErenumab-Aooe49$47,111
Nurtec OdtRimegepant Sulfate29$36,037
Emgality PenGalcanezumab-Gnlm28$27,303
AptiomEslicarbazepine Acetate14$24,258
UbrelvyUbrogepant19$23,596
RexultiBrexpiprazole12$21,629
Lacosamide105$20,634
NeuproRotigotine14$19,173
FycompaPerampanel13$17,867
Ajovy SyringeFremanezumab-Vfrm13$10,524
Carbidopa-LevodopaCarbidopa/Levodopa399$9,242
Memantine Hcl237$7,066
Entacapone71$6,915
Levetiracetam199$6,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$1,150$466,30082 claims
PfizerNurtec Odt$570$36,03729 claims
Sunovion Pharmaceuticals Inc.Aptiom$245$24,25814 claims
AbbVieUbrelvy$307$23,59619 claims
Otsuka America Pharmaceutical, Inc.Rexulti$107$21,62912 claims
UCB, Inc.Neupro$90$19,17314 claims
Upsher-smith Laboratories LLCTopiramate$40$1,13785 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 111 neurology providers in Mississippi.

Other neurology in Philadelphia

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →